Cargando…
What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?
Each year in the USA there are over 1 million hospital admissions directly related to heart failure (HF). With similar rates across Europe, this places a huge economic burden on healthcare systems globally. Hospitalisation for HF is associated with poor clinical outcomes with 25% of patients being r...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692046/ https://www.ncbi.nlm.nih.gov/pubmed/26719808 http://dx.doi.org/10.1136/openhrt-2015-000283 |
_version_ | 1782407227208892416 |
---|---|
author | Cannon, Jane A McKean, Andrew R Jhund, Pardeep S McMurray, John J V |
author_facet | Cannon, Jane A McKean, Andrew R Jhund, Pardeep S McMurray, John J V |
author_sort | Cannon, Jane A |
collection | PubMed |
description | Each year in the USA there are over 1 million hospital admissions directly related to heart failure (HF). With similar rates across Europe, this places a huge economic burden on healthcare systems globally. Hospitalisation for HF is associated with poor clinical outcomes with 25% of patients being readmitted with signs and symptoms of HF within 1 month of discharge and 10–20% dying in the 6 months after discharge. Although hospital admission could be a sign of disease progression, it is also possible that some of the treatments given acutely for example, inotropic therapy, may result in neurohormonal, haemodynamic and other effects accelerating end-organ damage and contributing to these poor outcomes after discharge. In contrast to the treatment of chronic heart failure (CHF), clinical trials conducted over the past decade in patients with acute HF (AHF) have failed to show significant reductions in morbidity or mortality despite some agents causing beneficial changes in symptoms. As such, the current treatment of patients hospitalised with HF is mainly based on consensus rather than clinical evidence and has changed little over time. We review RELAX-AHF in the context of the other key, large-scale AHF trials conducted over the past 15 years and compare and contrast study design and outcomes in an attempt to determine which factors might be associated with a successful trial in the future. |
format | Online Article Text |
id | pubmed-4692046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46920462015-12-30 What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Cannon, Jane A McKean, Andrew R Jhund, Pardeep S McMurray, John J V Open Heart Heart Failure and Cardiomyopathies Each year in the USA there are over 1 million hospital admissions directly related to heart failure (HF). With similar rates across Europe, this places a huge economic burden on healthcare systems globally. Hospitalisation for HF is associated with poor clinical outcomes with 25% of patients being readmitted with signs and symptoms of HF within 1 month of discharge and 10–20% dying in the 6 months after discharge. Although hospital admission could be a sign of disease progression, it is also possible that some of the treatments given acutely for example, inotropic therapy, may result in neurohormonal, haemodynamic and other effects accelerating end-organ damage and contributing to these poor outcomes after discharge. In contrast to the treatment of chronic heart failure (CHF), clinical trials conducted over the past decade in patients with acute HF (AHF) have failed to show significant reductions in morbidity or mortality despite some agents causing beneficial changes in symptoms. As such, the current treatment of patients hospitalised with HF is mainly based on consensus rather than clinical evidence and has changed little over time. We review RELAX-AHF in the context of the other key, large-scale AHF trials conducted over the past 15 years and compare and contrast study design and outcomes in an attempt to determine which factors might be associated with a successful trial in the future. BMJ Publishing Group 2015-12-23 /pmc/articles/PMC4692046/ /pubmed/26719808 http://dx.doi.org/10.1136/openhrt-2015-000283 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Heart Failure and Cardiomyopathies Cannon, Jane A McKean, Andrew R Jhund, Pardeep S McMurray, John J V What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
title | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
title_full | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
title_fullStr | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
title_full_unstemmed | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
title_short | What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? |
title_sort | what can we learn from relax-ahf compared to previous ahf trials and what does the future hold? |
topic | Heart Failure and Cardiomyopathies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692046/ https://www.ncbi.nlm.nih.gov/pubmed/26719808 http://dx.doi.org/10.1136/openhrt-2015-000283 |
work_keys_str_mv | AT cannonjanea whatcanwelearnfromrelaxahfcomparedtopreviousahftrialsandwhatdoesthefuturehold AT mckeanandrewr whatcanwelearnfromrelaxahfcomparedtopreviousahftrialsandwhatdoesthefuturehold AT jhundpardeeps whatcanwelearnfromrelaxahfcomparedtopreviousahftrialsandwhatdoesthefuturehold AT mcmurrayjohnjv whatcanwelearnfromrelaxahfcomparedtopreviousahftrialsandwhatdoesthefuturehold |